Vaxcyte, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+5.31%
vs ±8.6% implied · ×0.62
shaded = implied · ▲▼ = realized
Vaxcyte has 4 disclosed suppliers and 0 disclosed customers in SEC filings.
Vaxcyte, Inc.
62.02
SentenceIn September 2025, we announced a new agreement with Patheon Manufacturing Services, LLC, part of Thermo Fisher Scientific (collectively, "Thermo Fisher") to provide custom commercial fill-finish capacity for our broad-spectrum PCVs at Thermo Fisher's Greenville, North Carolina facility.
SentenceLonza will be a preferred, non-exclusive, supplier of the Products to us, and we retain the right to procure the Products from one or more alternate and/or backup manufacturers of the Products (including at our own facilities).
PCVX 10-Kaccession 0001649094-26-000007
SentenceIn November 2023, we entered into a manufacturing rights agreement (the "Manufacturing Rights Agreement") with Sutro Biopharma pursuant to which we obtained exclusive rights to independently, or through certain third parties, develop, improve and manufacture cell-free extract for use in connection with our vaccine candidates.
PCVX 10-Kaccession 0001649094-26-000007
SentenceWe are party to a license agreement with the University of California, San Diego, dated February 4, 2019, which was subsequently amended on August 16, 2019 (as amended, the "UCSD License") whereby we are the exclusive licensee of an issued U.S. patent and pending U.S. patent application related to a non-cross-reactive Group A Strep carbohydrate antigen and methods of producing the antigen.
PCVX 10-Kaccession 0001649094-26-000007
—
Linked news
NewsExpected move
Inputs8Q avg ±5.3%·×1.38·rich
straddle ±11.1%
spot 62.03exp Nov 20ATM strike 60ATM straddle 8.07IV 67%